Events

May 20, 2025

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

Industry veteran to support acceleration of key pipeline projects and novel BiTAC antibody formats towards clinical studies.

May 5, 2025

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

The partnership combines VERAXA's proprietary ADC technology with OmniAb's antibody discovery technology for novel therapies targeting solid tumors.

April 23, 2025

‍VERAXA and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies.